Page last updated: 2024-11-05

sodium citrate, anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sodium Citrate: Sodium salts of citric acid that are used as buffers and food preservatives. They are used medically as anticoagulants in stored blood, and for urine alkalization in the prevention of KIDNEY STONES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sodium citrate : The trisodium salt of citric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6224
CHEMBL ID1355
CHEBI ID53258
MeSH IDM0582745

Synonyms (92)

Synonym
AC-15008
994-36-5
sodium citrate (na3c6h5o7)
hsdb 5201
trisodium 2-hydroxy-1,2,3-propanetricarboxylate
trisodium citrate, anhydrous
natrocitral
citreme
ccris 3293
1,2,3-propanetricarboxylic acid, 2-hydroxy-, trisodium salt
sodium citrate anhydrous
citric acid, trisodium salt
citrosodna
citnatin
citrosodine
trisodium citrate
fema no. 3026
2-hydroxy-1,2,3-propanetricarboxylic acid, trisodium salt
einecs 200-675-3
citrosodina
anhydrous sodium citrate
sodium citrate, anhydrous
D05855
68-04-2
sodium citrate (usp)
sodium citrate
citric acid trisodium salt, anhydrous, >=98% (gc)
natrii citras, dehydrate
ins-331(iii)
e-331(iii)
sodium citrate,anhydrous
anhydrous trisodium citrate
CHEMBL1355
fema no. 3026, anhydrous-
anticoagulant sodium citrate
natrii citras
sodium citrate hydrous
e331
ins no.331(iii)
citric acid trisodium salt
chebi:53258 ,
trisodium 2-hydroxypropane-1,2,3-tricarboxylate
c6h5na3o7
einecs 213-618-2
pneucid
e 331
bicitra
sodium 2-hydroxy-1,2,3-propanetricarboxylate
rs7a450lga ,
unii-rs7a450lga
ec 200-675-3
1,2,3-propanetricarboxylic acid, 2-hydroxy-, sodium salt (1:3)
FT-0623960
natrii citras [who-ip latin]
anhydrous trisodium citrate [ii]
sodium citrate [mi]
sodium citrate, anhydrous [who-ip]
sodium citrate anhydrous [hsdb]
anhydrous trisodium citrate [usp monograph]
trisodium-citrate
sodium citrate [who-ip]
sodium citrate,anhydrous [vandf]
AKOS015915009
sodium citrate dihydrate usp fine granular
HRXKRNGNAMMEHJ-UHFFFAOYSA-K
tri-sodium citrate
sodium citrate salt
2-hydroxy-1,2,3-propanenetricarboxylic acid trisodium salt dihydrate
sodium 2-hydroxypropane-1,2,3-tricarboxylate
DTXSID2026363
trisodium citrate anhydrous
mfcd00012462
DB09154
J-520101
citric acid trisodium salt, vetec(tm) reagent grade, 98%
citric acid trisodium salt, 99%
sodium (iii) citrate
sodium citrate, unspecified form
1Q73Q2JULR ,
sodium citrate, unspecified
Q409728
D77308
trisodium;2-hydroxypropane-1,2,3-tricarboxylate
8055-55-8
EN300-74572
citrate concentrated solution
sodium citrate (ii)
oracit
modified shohl's solution
sodium citrate (usp impurity)
albright's solution
sodium citrate (usp-rs)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This property was attributed to a change in U speciation, characterized by the occurrence of U(VI)-citrate complexes, which were supposed to be more toxic than U(VI)-bicarbonate."( Citrate does not change uranium chemical speciation in cell culture medium but increases its toxicity and accumulation in NRK-52E cells.
Avoscan, L; Carrière, M; Gouget, B; Milgram, S; Proux, O; Thiebault, C, 2006
)
0.33
" A safe and simple "regional" anticoagulation strategy would be beneficial."( Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.
Clark, JA; Golper, TA; Schulman, G, 2008
)
0.35
" Safe and effective regional citrate anticoagulation can be performed in 8-h sustained low-efficiency dialysis without metabolic complications with laboratory surveillance only before and after sustained low-efficiency dialysis treatment; however, certain safeguards are mandatory."( Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.
Clark, JA; Golper, TA; Schulman, G, 2008
)
0.35
" No major adverse events were reported."( Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia.
Ashman, N; Miller, M; Nolan, J; Winnett, G, 2008
)
0.35
" In this article, we provide a safe and an easy-to-handle citrate anticoagulation protocol with variable treatment doses and excellent control of the acid-base status."( A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.
Kindgen-Milles, D; Morgera, S; Neumayer, HH; Peters, H; Schneider, M; Slowinski, T; Vargas-Hein, O; Zuckermann-Becker, H, 2009
)
0.35
"We provide a safe and an easy-to-handle citrate anticoagulation protocol that allows an excellent acid-base and electrolyte control in critically ill patients with acute renal failure."( A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.
Kindgen-Milles, D; Morgera, S; Neumayer, HH; Peters, H; Schneider, M; Slowinski, T; Vargas-Hein, O; Zuckermann-Becker, H, 2009
)
0.35
"No clinically relevant adverse effects on haemodynamics were encountered, apart from a decrease in cardiac output and mixed venous saturation similar to that in control animals."( Intraoperative blood salvage and retransfusion from citrate treated wounds is safe and feasible.
Olsson, C; Olsson, P; Owall, A; Rådegran, K, 2010
)
0.36
"The technique was safe and feasible for intraoperative blood salvage and autotransfusion."( Intraoperative blood salvage and retransfusion from citrate treated wounds is safe and feasible.
Olsson, C; Olsson, P; Owall, A; Rådegran, K, 2010
)
0.36
" The gold nanoparticles in solution prepared using the citrate reduction method is found not to be toxic or mutagenic but photomutagenic to the bacteria; however, careful control experiments indicate that the photomutagenicity is due to the co-existing citrate and Au³⁺ ions, not due to the gold nanoparticle itself."( Toxic effects of gold nanoparticles on Salmonella typhimurium bacteria.
Lawson, R; Ray, PC; Wang, S; Yu, H, 2011
)
0.37
" Since the impact of these nanomaterials on health and environment remains undefined, research on their possible toxic effects has attracted considerable attention."( Cyto and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral blood mononuclear cells.
Antunes, LM; de Oliveira, Rde C; Marangoni, VS; Paino, IM; Zucolotto, V, 2012
)
0.38
" We analysed a large cohort of patients with acute kidney injury (AKI) treated by the former method and hypothesized that it is safe and efficacious."( Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.
Groeneveld, AB; Jallah, BP; Nurmohamed, SA; ter Wee, PM; Vervloet, MG; Yldirim, G, 2013
)
0.39
"In critically ill, patients with AKI at high risk of bleeding, CVVH with citrate-containing replacement solution is safe and efficacious."( Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study.
Groeneveld, AB; Jallah, BP; Nurmohamed, SA; ter Wee, PM; Vervloet, MG; Yldirim, G, 2013
)
0.39
"These results show that RCA is superior to heparin-based anticoagulation in terms of delivered RRT dose and filter life span and is a safe and feasible method."( Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.
Martin, PY; Ponte, B; Pugin, J; Saudan, P; Stucker, F; Tataw, J; Wozniak, H, 2015
)
0.42
" In the present work, mussel hemocytes and gill cells were used to assess the potential toxic effects of Au, ZnO and SiO2 NPs with different sizes and shapes in parallel with their respective ionic and bulk forms and additives used in the NPs preparations."( Cytotoxicity of Au, ZnO and SiO₂ NPs using in vitro assays with mussel hemocytes and gill cells: Relevance of size, shape and additives.
Arostegui, I; Cajaraville, MP; Gilliland, D; Katsumiti, A; Oron, M; Valsami-Jones, E, 2016
)
0.43
" The primary end-point was the occurrence of hydraulic resistance and secondary safety end-point was adverse drug reactions related to the lock solutions."( The CLOCK trial, a double-blinded randomized controlled trial: Trisodium citrate 30% and minocycline 3 mg/mL plus EDTA 30 mg/mL are effective and safe for catheter patency maintenance among CKD 5D patients on hemodialysis.
Luiz, MV; Scavone, C; Tzanno, C, 2017
)
0.46
"Cadmium (Cd), classified as human carcinogen, is an extremely toxic heavy metal pollutant, and there is an increasing environmental concern for cadmium exposure through anthropogenic sources including cigarette smoke."( Effect of surfactant in mitigating cadmium oxide nanoparticle toxicity: Implications for mitigating cadmium toxicity in environment.
Anthony, SP; Balmuri, SR; Golokhvast, KS; Kumar, VV; Raman, T; Selvaraj, U; Tsatsakis, AM, 2017
)
0.46
"Citrate represents a safe and effective anticoagulant for SLED for cancer patients with AKI undergoing treatment in the intensive care unit."( Efficacy and Safety of Regional Anticoagulation with 4% Trisodium Citrate Versus Heparin in Extended Hemodialysis among Critical Patients with Cancer and Acute Kidney Injury.
Alves, JA; Andrade, LAS; Baptista, AL; de Brito, GA; Imanishe, MH; Moura, EIM; Pereira, BJ, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic data could provide a basis for the clinical use of citrate anticoagulation in critically ill patients."( Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.
Bauer, E; Gangl, A; Gendo, A; Joukhadar, C; Kramer, L; Madl, C; Strobl, W, 2003
)
0.32
" The Tmax of IBU-ISG and reference formulation were (1."( [Preparation of in situ gel systems for the oral delivery of ibuprofen and its pharmacokinetics study in beagle dogs].
He, ZG; Song, HT; Wu, RL; Xie, JW; Yi, SL; Zhao, CS, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The influence of weak organic acids and trisodium citrate in combination with a high or a reduced water activity (aw) was investigated when a population of Arcobacter butzleri was exposed to a low concentration of acetic or citric acid, and trisodium citrate combined with high (0."( The effect of acetic acid, citric acid, and trisodium citrate in combination with different levels of water activity on the growth of Arcobacter butzleri in culture.
Cervenka, L; Malíková, Z; Vytrasová, J; Zachová, I, 2004
)
0.32
" cerevisiae CGMCC 2842 (wild type), improvement of methionine and ATP availability through MET6 and SAM2 co-expression combined with sodium citrate feeding was investigated here."( Improving methionine and ATP availability by MET6 and SAM2 co-expression combined with sodium citrate feeding enhanced SAM accumulation in Saccharomyces cerevisiae.
Chen, H; Dou, J; Wang, Z; Zhou, C, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"The poor bioavailability and therapeutic response exhibited by the conventional ophthalmic solutions due to precorneal elimination of the drug may be overcome by the use of in situ gel forming systems that are instilled as drops into the eye and undergo a sol-gel transition in the cul-de-sac."( Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride.
Balasubramaniam, J; Pandit, JK,
)
0.13
"In the current study, the influence of chitosan on the dissolution rate and bioavailability of acyclovir has been illustrated through the preparation of co-crystals by simple solvent change method."( Formulation and physicochemical characterization of chitosan/acyclovir co-crystals.
Allam, AN; El Gamal, SS; Naggar, VF,
)
0.13
" Linear and nonlinear (quadratic, cubic, sigmoid functions) deconvolution based in vitro-in vivo correlation (IVIVC) models were developed using in vitro dissolution data and bioavailability profile."( Chronotherapeutic delivery of hydroxypropylmethylcellulose based mini-tablets: an in vitro-in vivo correlation.
Biswas, N; Guha, A; Kuotsu, K; Sahoo, RK, 2014
)
0.4
" Sodium citrate, SDS and deoxysodium cholate serve as excellent absorption enhancers which are useful for the related research improving the oral bioavailability of OMT."( Absorption mechanism of oxymatrine in cultured Madin-Darby canine kidney cell monolayers.
Cen, MF; Cheng, XG; Huang, LH; Wang, GX; Wang, SJ; Xiong, XH; Zang, LQ; Zhong, YM, 2016
)
0.43
"Iron bioavailability nearly doubled when CA/TSC was extruded with FePP into fortified rice, resulting in iron bioavailability comparable to that of FeSO4 We attribute this effect to an in situ generation of soluble FePP citrate moieties during extrusion and/or cooking because of the close physical proximity of FePP and CA/TSC in the extruded rice matrix."( Cofortification of ferric pyrophosphate and citric acid/trisodium citrate into extruded rice grains doubles iron bioavailability through in situ generation of soluble ferric pyrophosphate citrate complexes.
Adelmann, H; Cercamondi, CI; Hackl, L; Moretti, D; Wild, D; Zeder, C; Zimmermann, MB, 2016
)
0.43
" Although dissolution profiles similar to the original product were obtained, the unexpected results of omeprazole low bioavailability in the fed bioequivalence study (BES I) showed the necessity to investigate the formulation in greater depth."( The effect of the composition of a fixed dose combination on bioequivalence results.
Beránek, J; Červená, T; Dumicic, A; Franc, A; Hofmann, J; Kukačková, L; Repický, A; Šalandová, J; Srbek, J; Vetchý, D; Vladovičová, B, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
"We compared biliary and urinary aluminium (Al) excretion following ingestion of dietary or gavage dosing of low to moderate pharmacological doses of aluminium."( Effect of the size of an oral dose of aluminium on the relative importance of biliary v. urinary aluminium excretion in conscious rats.
Greger, JL; Sutherland, JE, 1998
)
0.3
" After a 14-h fasting period, animals were dosed orally with deionized water, or 2 mmol Al chloride, or 2 mmol Al chloride plus 2 mmol Na citrate."( Effect of oral aluminum and aluminum citrate on blood level and short-term tissue distribution of aluminum in the rat.
Coudray, C; Deng, Z; Gouzoux, L; Mazur, A; Pépin, D; Rayssiguier, Y, 1998
)
0.3
" These findings indicate that dosing regimens for GPIIb/IIIa receptor antagonists based on the platelet inhibition profile in citrate may provide misleading information with respect to their true in vivo antithrombotic efficacy."( Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.
Faul, JD; Huang, J; Lucchesi, BR; Rebello, SS, 2000
)
0.31
" ISI interchange between these glass and PET tubes could induce INR differences amounting to 14%, which could affect clinical dosage of oral anticoagulants."( A comparison of two sodium citrate concentrations in two evacuated blood collection systems for prothrombin time and ISI determination.
Chantarangkul, V; Tripodi, A; van den Besselaar, AM, 2000
)
0.31
"The objective of the present work was to improve the dissolution properties of the poorly water-soluble drug meloxicam by preparing solid dispersions with hydroxyethyl cellulose (HEC), mannitol and polyethylene glycol (PEG) 4000 and to develop a dosage form for geriatric population."( Solid dispersion of meloxicam: factorially designed dosage form for geriatric population.
Dahiya, S; Pathak, D; Pathak, K, 2008
)
0.35
" These parameters can be judiciously used in predicting and modifying drug release from dosage forms."( Cross-linked chitosan films: effect of cross-linking density on swelling parameters.
Rana, V; Tiwary, AK, 2010
)
0.36
" Furthermore, the shape and size of the products can be further manipulated by adjusting the dosage of Cit(3-) and pH values in the initial solution."( Highly uniform and monodisperse GdOF:Ln3+ (Ln = Eu, Tb, Tm, Dy, Ho, Sm) microspheres: hydrothermal synthesis and tunable-luminescence properties.
Cheng, Z; Geng, D; Kang, X; Li, X; Lian, H; Lin, J; Shang, M; Wu, Y; Zhang, Y, 2013
)
0.39
" On-chip recalcification and drug dosing of citrated blood allows for assays of platelet function in a whole blood milieu under flow."( Rapid on-chip recalcification and drug dosing of citrated whole blood using microfluidic buffer sheath flow.
Diamond, SL; Muthard, RW, 2014
)
0.4
" The dosage of the drug varied from 6 to 18 g per day and was selected individually, depending on the purpose of the appointment of Blemaren®."( [EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS].
Konstantinova, OV; Yanenko, EK,
)
0.13
" The dosage of SC, C:Fe, initial pH and Cr(Ⅵ) concentration demonstrated direct effects on the removal efficiency."( Sodium citrate and biochar synergistic improvement of nanoscale zero-valent iron composite for the removal of chromium (Ⅵ) in aqueous solutions.
Baig, SA; Huang, N; Ma, M; Ye, M; Zhao, Y; Zhou, H, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
flavouring agentA food additive that is used to added improve the taste or odour of a food.
anticoagulantAn agent that prevents blood clotting.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Homo sapiens (human)Ki2,160.00000.00000.72369.9200AID238528; AID414637
Carbonic anhydrase 4Homo sapiens (human)Ki0.09900.00021.97209.9200AID238529
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki1,670.00000.00001.27259.9000AID238510
Carbonic anhydrase 9Homo sapiens (human)Ki4,930.00000.00010.78749.9000AID238530
Carbonic anhydraseCandida albicans SC5314Ki39.10000.01051.44448.3470AID414639
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID414637Inhibition of human carbonic anhydrase22009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates.
AID238792Binding affinity against human cytosolic Carbonic anhydrase I (A = activator)2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
AID414638Inhibition of Cryptococcus neoformans Can22009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates.
AID1678470Metal chelating activity assessed as Fe2+-compound complex formation incubated for 5 mins by colorimetry2020ACS medicinal chemistry letters, Nov-12, Volume: 11, Issue:11
Covalent Bridging of Corilagin Improves Antiferroptosis Activity: Comparison with 1,3,6-Tri-
AID414639Inhibition of Candida albicans Nce1032009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with aliphatic and aromatic carboxylates.
AID238510Binding affinity against human cytosolic Carbonic anhydrase V2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
AID238529Binding affinity against human cytosolic Carbonic anhydrase IV2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
AID238530Binding affinity against human cytosolic Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
AID238528Binding affinity against human cytosolic Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (913)

TimeframeStudies, This Drug (%)All Drugs %
pre-199096 (10.51)18.7374
1990's68 (7.45)18.2507
2000's283 (31.00)29.6817
2010's371 (40.64)24.3611
2020's95 (10.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.65 (24.57)
Research Supply Index6.99 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index53.51 (26.88)
Search Engine Supply Index2.92 (0.95)

This Compound (27.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials113 (11.64%)5.53%
Reviews23 (2.37%)6.00%
Case Studies35 (3.60%)4.05%
Observational5 (0.51%)0.25%
Other795 (81.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]